Eli Lilly Reports Pirtobrutinib Clinical Trial Results with 87% ORR
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Clinical Trial Success: In the BRUIN CLL-314 study, pirtobrutinib achieved an overall response rate (ORR) of 87.0%, significantly higher than 78.5% for ibrutinib, indicating its superior efficacy in treating chronic lymphocytic leukemia (CLL) and potentially changing treatment standards.
- Favorable Survival Trends: Although progression-free survival (PFS) data are still immature, pirtobrutinib demonstrated a 76% reduction in the risk of disease progression or death in treatment-naïve patients, suggesting its potential in early treatment and likely attracting more patients to this therapy.
- Large Study Scale: The study enrolled 662 patients, randomized into pirtobrutinib (331) and ibrutinib (331) groups, providing robust statistical support for the drug's efficacy and further validating its application prospects in clinical settings.
- Good Safety Profile: The safety profile of pirtobrutinib was similar to previous studies, with significantly lower rates of adverse events such as atrial fibrillation and hypertension compared to ibrutinib, indicating its advantages in clinical use and potentially enhancing patient adherence to treatment.
LLY.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1035 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1014.490
Low
800.00
Averages
1035
High
1300
Current: 1014.490
Low
800.00
Averages
1035
High
1300
BMO Capital
Outperform
maintain
2025-12-04
New
Reason
BMO Capital
Price Target
2025-12-04
New
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Eli Lilly to $1,200 from $1,100 and keeps an Outperform rating on the shares. Following a string of positive readouts from Lilly's obesity pipeline Orforglipron and Eloralintide, the firm is assessing the potential scenarios for the upcoming TRIUMPH-4 readout for Retatrutide, the analyst tells investors in a research note, adding that BMO is anticipating 20%-23% weight loss and 50% or more in WOMAC pain score reduction as the base case. The firm adds that it believes diabetes will lead to durable and sustained growth for Eli Lilly as its pipeline strategy is beginning to bear fruit.
Guggenheim
Buy
maintain
2025-12-03
New
Reason
Guggenheim
Price Target
2025-12-03
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Eli Lilly (LLY) to $1,163 from $1,036 and keeps a Buy rating on the shares after updating the firm's Lilly and Novo Nordisk (NVO) models to reflect prescription trends and GLP-1 pricing updates and announcements. While noting that Lilly has "delivered another impressive year of stock performance in 2025," the firm "simply cannot argue with the company's superior overall execution capitalizing fully on the Pharma mega cycle of our lifetime," the analyst tells investors.
Morgan Stanley
NULL
to
Overweight
maintain
2025-11-24
Reason
Morgan Stanley
Price Target
2025-11-24
maintain
NULL
to
Overweight
Reason
Morgan Stanley raised the firm's price target on Eli Lilly to $1,290 from $1,171 and keeps an Overweight rating on the shares. The firm refreshed its model assumptions to incorporate recent developments in the GLP-1 space as well as insights from a proprietary primary care physician survey, the analyst tells investors.
Bernstein
Outperform
maintain
2025-11-24
Reason
Bernstein
Price Target
2025-11-24
maintain
Outperform
Reason
Bernstein raised the firm's price target on Eli Lilly to $1,300 from $1,100 and keeps an Outperform rating on the shares. The firm cites a catalyst path and earnings upside over the next 24 months-plus driven by Orforglipron launch, Trump GLP1 deal and ex-U.S. expansion.
See All Ratings
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why did Eli Lilly reduce prices for its weight-loss drug Zepbound?
What factors contributed to Eli Lilly achieving a $1 trillion market cap?
Will Eli Lilly's price cuts for Zepbound increase its market share significantly?
How might Novo Nordisk's price reductions impact Eli Lilly's competitive position?